ASTERDM Aster DM Healthcare Q3 FY25 results (Oct–Dec 2024) and concall
Aster DM Health delivered a strong 9M FY25 performance characterized by significant margin expansion and robust ARPOB growth. The company is undergoing a transformative merger with QCIL to become one of India's largest healthcare providers while simultaneously executing an aggressive brownfield expansion plan. Management remains focused on high-end specialty mix (Oncology/Neuro) and operational efficiencies to drive consolidated margins toward a 21% target by FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 1,086 | 1,050 |
| EBITDA | 217 | 186 |
| Net profit | 106 | 64 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
